

## ASX Release

### Appendix 4C – Q2 2018 Quarterly Cash Flow Report

30th July 2018 – Sydney, Australia– Oneview Healthcare PLC (ASX:ONE) today released its Appendix 4C – Quarterly Cashflow report for the period ending 30 June 2018.

#### Financial Highlights

Operating cash outflows for the quarter were approximately €4.98 million which included

- Receipts from customers of €2.47 million;
- Payments for staff costs in the quarter amounted to €4.38 million, which compares to €4.77 million in the prior quarter and €5.27 million in the prior corresponding quarter.
- Direct costs incurred for hardware and implementation amounted to €1.24 million (€0.53 million for the prior quarter), while administration and corporate costs were €0.66 million inclusive of unrealised foreign exchange gains of €0.51 million.

Cash balances as at 30 June amounted to €17.47 million.

#### Operational Highlights

In May, we announced an expansion in our global footprint with the signing of a new contract with Bumrungrad International Hospital (Bumrungrad”) in Bangkok, Thailand. This is our first entry into the medical tourism market in South East Asia and was one of our strategic priorities announced at the time of our initial public offering. This win also reaffirms the global appeal of the Oneview platform. The new three-year contract involves deploying the Oneview solution in 497 beds and 110 digital signage locations at Bumrungrad’s flagship hospital at Sukhumvit 3 in Bangkok. This project is scheduled for delivery commencing in 2018 and concluding early in 2019.

In addition, we announced that an existing Oneview customer, Mediclinic Middle East in the UAE, (part of Mediclinic International PLC, a private healthcare company with operations in Southern Africa, Switzerland and the United Arab Emirates), has signed an extension agreement to deploy the Oneview inpatient solution at their new Mediclinic Parkview Hospital to enhance patient entertainment and engagement. The new hospital is expected to open to the public in October 2018. The Oneview solution will be deployed across 168 patient rooms and 144 digital signage locations in H2 2018

The company delivered the first version of its new Gen 3 Android product to 374 rooms in the Kimmel Pavilion at NYU Langone during the quarter.

The company completed quality assurance testing of the first 1,500 units of Android hardware during the quarter. This hardware is currently in transit to customers in Australia and the United States with plans for installation in H2 2018 and Q1 2019.

Full time headcount at the end of June was 150 (June 2017: 178).

### **About Oneview Healthcare**

Oneview provides interactive healthcare technologies for patients, families and caregivers. Oneview's technology weaves a facility's existing disparate systems into a single seamless platform, allowing healthcare facilities to engage patients in meaningful ways, improve communication, and streamline clinical workflows. Patients enjoy the comfort and convenience of information, education, entertainment and environmental controls at the bedside, while facilities enjoy better health outcomes and staff satisfaction.

Enquiries: John Kelly, CFO or James Fitter, CEO

Oneview Healthcare

Website : [www.oneviewhealthcare.com](http://www.oneviewhealthcare.com)

## Appendix 4C

## Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

## Name of entity

Oneview Healthcare PLC

## ABN

610 611 768

## Quarter ended ("current quarter")

30<sup>th</sup> June 2018

Consolidated statement of cash flows	Current quarter €'000	Year to date (6 months) €'000
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	2,465	3,816
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(1,236)	(1,770)
(c) advertising and marketing	(196)	(439)
(d) leased assets	-	-
(e) staff costs	(4,378)	(9,152)
(f) administration and corporate costs	(656)	(2,363)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material) – incl. general working capital movements.	(983)	(893)
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(4,984)</b>	<b>(10,801)</b>

Consolidated statement of cash flows		Current quarter €'000	Year to date (6 months) €'000
<b>2.</b>	<b>Cash flows from investing activities</b>		
2.1	Payments to acquire:		
	(a) property, plant and equipment	(166)	(314)
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	-	-
	(b) businesses (see item 10)	-	-
	(c) investments	-	-
	(d) intellectual property	-	-
	(e) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(166)</b>	<b>(314)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of shares	-	-
3.2	Proceeds from issue of convertible notes	-	-
3.3	Proceeds from exercise of share options	-	3
3.4	Transaction costs related to issues of shares, convertible notes or options	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>-</b>	<b>3</b>

Consolidated statement of cash flows		Current quarter €'000	Year to date (6 months) €'000
<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of quarter/year to date	22,375	28,611
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(4,984)	(10,801)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(166)	(314)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	3
4.5	Effect of movement in exchange rates on cash held	243	(31)
<b>4.6</b>	<b>Cash and cash equivalents at end of quarter</b>	<b>17,468</b>	<b>17,468</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter €'000	Previous quarter €'000
5.1	Bank balances	17,468	22,375
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>17,468</b>	<b>22,375</b>

6.	Payments to directors of the entity and their associates	Current quarter €'000
6.1	Aggregate amount of payments to these parties included in item 1.2	297
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

7.	Payments to related entities of the entity and their associates	Current quarter €'000
7.1	Aggregate amount of payments to these parties included in item 1.2	-
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3	Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

8.	<b>Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>	<b>Total facility amount at quarter end €'000</b>	<b>Amount drawn at quarter end €'000</b>
8.1	Loan facilities	-	-
8.2	Credit standby arrangements	-	-
8.3	Other (please specify)	-	-
8.4	Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

9.	<b>Estimated cash outflows for next quarter</b>	<b>€'000</b>
9.1	Research and development	-
9.2	Product manufacturing and operating costs	(1,265)
9.3	Advertising and marketing	(94)
9.4	Leased assets	-
9.5	Staff costs	(4,283)
9.6	Administration and corporate costs	(1,126)
9.7	Other (provide details if material)	-
9.8	<b>Total estimated cash outflows</b>	<b>(6,768)</b>

10.	Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1	Name of entity	-	-
10.2	Place of incorporation or registration	-	-
10.3	Consideration for acquisition or disposal	-	-
10.4	Total net assets	-	-
10.5	Nature of business	-	-

### Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:  .....  
(Director)

Date: 30 July 2018

Print name: John Kelly

### Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.